# Insulin: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on insulin — the prototype FDA-approved therapeutic peptide. Grade-A human evidence in diabetes, a tyrosine-kinase mechanism, and a stark warning on lethal non-medical 'anabolic' misuse.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Insulin is the **gold-standard, Grade-A therapeutic peptide** — the molecule that proved peptides could be real, manufacturable, life-saving medicine. It is life-sustaining in type 1 diabetes and a core glucose-lowering tool in type 2, backed by decades of RCTs and global guidelines.[9](https://peptidevox.com/#r9) The same potent anabolic biology has driven **dangerous, sometimes fatal non-medical misuse** by bodybuilders, for which there is no legitimate indication and a WADA all-times ban.[11](https://peptidevox.com/#r11)

Insulin is the prototypical therapeutic peptide hormone and the anchor of the claim that "peptides are real medicine": a 51-amino-acid, two-chain protein that became, as recombinant Humulin in 1982, the first FDA-approved drug of any kind made by recombinant-DNA technology.[18](https://peptidevox.com/#r18)[19](https://peptidevox.com/#r19) This monograph separates what is proven — and it is a great deal — from the one place where insulin is hyped and lethal.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Insulin is a high-alert medication: dosing errors and non-prescribed use can cause fatal hypoglycemia. Dosing figures are reported strictly as seen in clinical guidelines and the published literature for completeness. Consult a licensed clinician for any diabetes or metabolic care.*

## What is insulin and how does it work?

Insulin is a peptide hormone of 51 amino acids arranged as two chains — an A-chain (21 residues) and a B-chain (30 residues) — held together by two interchain disulfide bonds, with a third intrachain disulfide in the A-chain. Secreted by pancreatic beta-cells, it is a highly potent anabolic hormone central to glucose, lipid and protein metabolism.[2](https://peptidevox.com/#r2) Therapeutic insulin is now produced by recombinant DNA in *E. coli* or yeast rather than extracted from pig or cow pancreas as it was historically.[4](https://peptidevox.com/#r4)

Insulin acts on the insulin receptor (IR), a receptor tyrosine kinase that is structurally unusual — a preformed, covalently linked alpha-2-beta-2 tetramer rather than a single-chain RTK.[2](https://peptidevox.com/#r2) Insulin binding to the alpha-subunits induces a large conformational change that activates the beta-subunit kinase, triggering trans-autophosphorylation and recruitment of insulin-receptor-substrate (IRS) proteins; phosphorylated IRS then activates two principal cascades — the PI3K-AKT pathway (mediating GLUT4-driven glucose uptake, glycogen synthesis, lipogenesis and protein synthesis via mTOR) and the RAS-MAPK pathway (mediating growth and mitogenic signaling).[1](https://peptidevox.com/#r1)[3](https://peptidevox.com/#r3) The net physiologic effect is suppression of hepatic glucose output, stimulation of peripheral glucose uptake, and a broad anabolic program — the same anabolic biology misused for muscle gain.

Because insulin is a peptide, it is destroyed by gastrointestinal peptidases and first-pass hepatic metabolism, so it is not orally bioavailable — the central reason injection has remained the mainstay and why "oral insulin" remains an unsolved delivery problem.[26](https://peptidevox.com/#r26) The therapeutic analog landscape engineers the subcutaneous absorption profile: rapid-acting analogs (lispro, aspart, glulisine) dissociate quickly from hexamers to monomers for an earlier peak and better prandial coverage with less late hypoglycemia, while long-acting basal analogs (glargine, detemir, degludec) give a flatter, roughly 24-hour peakless profile. In a randomized double-blind glucose-clamp crossover study, glargine held plasma glucose stable out to 24 hours whereas detemir waned after about 16 hours.[7](https://peptidevox.com/#r7) Inhaled insulin (Afrezza) sidesteps GI degradation entirely, with the fastest action of any approved insulin.[23](https://peptidevox.com/#r23)[24](https://peptidevox.com/#r24)

## What is the evidence by indication?

Unlike most peptides in this encyclopedia, insulin's evidence is overwhelmingly *human* and overwhelmingly strong. The American Diabetes Association Standards of Care codify its role across every major indication.[9](https://peptidevox.com/#r9)

  Insulin evidence by indication

    IndicationBest evidenceGrade

    Type 1 diabetes (replacement)Life-sustaining; extensive RCTs; basal-bolus analog standard of careA
    Type 2 diabetes (glucose lowering)RCTs on initiation thresholds & analog-vs-NPH; ORIGIN (n=12,537)A
    Analog & biosimilar equivalenceHead-to-head RCTs (lispro vs aspart); Semglee INSTRIDE interchangeabilityA
    Diabetic ketoacidosis / inpatient crisesIV regular insulin is standard of care (placebo-controlling would be unethical)A/B
    "Anabolic" / muscle-building in non-diabeticsNo controlled human evidence; case reports of coma & deathD

In type 1 diabetes insulin is absolutely required — there is no alternative to exogenous insulin for absolute insulin deficiency, and basal-bolus analog regimens are the guideline-recommended standard.[9](https://peptidevox.com/#r9) In type 2 diabetes, basal insulin (often added to metformin, an SGLT2 inhibitor or a GLP-1 receptor agonist) reliably lowers HbA1c when non-insulin therapy is insufficient, and analogs reduce nocturnal and overall hypoglycemia versus NPH while achieving similar A1c.[5](https://peptidevox.com/#r5) The large ORIGIN RCT showed glargine was cardiovascular-neutral and did not raise overall cancer incidence versus standard care.[20](https://peptidevox.com/#r20) Head-to-head trials and systematic reviews further establish that rapid analogs lispro and aspart are clinically equivalent, and that the interchangeable biosimilar Semglee matches reference Lantus on PK/PD, efficacy, safety and immunogenicity.[6](https://peptidevox.com/#r6)[27](https://peptidevox.com/#r27) For diabetic ketoacidosis and inpatient hyperglycemia, IV regular insulin is the established treatment, codified in guidance rather than tested against placebo because withholding insulin would be unethical.[9](https://peptidevox.com/#r9)

Proven vs hyped
Proven in humans: glucose control in type 1 and type 2 diabetes, crisis management and pregnancy — all standard of care.[9](https://peptidevox.com/#r9) Hyped and dangerous: any "anabolic" muscle-building use in healthy people, which has **no controlled efficacy evidence**, carries a high risk of fatal hypoglycemia, and is prohibited in sport.[12](https://peptidevox.com/#r12)

## What doses appear in the literature?

Reported strictly as information from clinical guidelines, not a protocol. Insulin is a high-alert medication; dosing must be individualized and clinician-supervised. For type 1 diabetes the literature figure in metabolically stable adults is roughly 0.5 U/kg/day total, split about 50% basal and 50% prandial, with lower weight-based doses (0.2-0.6 U/kg/day) during the honeymoon period, in children, or with residual beta-cell function.[9](https://peptidevox.com/#r9) For type 2 diabetes, basal initiation is commonly 0.1-0.2 U/kg/day (or a flat 10 U/day), titrated to fasting glucose while continuing metformin, SGLT2 inhibitors or GLP-1 receptor agonists; the 2025 ADA update replaced the old ">0.5 U/kg/day" over-basalization threshold with functional criteria.[10](https://peptidevox.com/#r10) Routes include subcutaneous (vial, pen or pump) for routine care, intravenous regular insulin for crises, and inhaled Afrezza as a mealtime option carrying a boxed warning.[23](https://peptidevox.com/#r23) Although manufacturers caution against mixing glargine with rapid analogs, clamp studies have not shown deleterious effects on glucose excursions when mixed.[8](https://peptidevox.com/#r8)

## How safe is insulin, and what is the misuse danger?

Insulin's defining hazard is hypoglycemia; severe untreated hypoglycemia causes seizures, coma and death, and analogs reduce but do not eliminate the risk.[9](https://peptidevox.com/#r9)[5](https://peptidevox.com/#r5) Other adverse effects include weight gain, injection-site lipohypertrophy, hypokalemia (insulin drives potassium intracellularly, relevant at high or IV doses and in DKA), and rare hypersensitivity. A theoretical mitogenicity concern — because the IR is homologous to the IGF-1 receptor, glargine shows greater in-vitro IGF-1R affinity than human insulin — has been largely resolved reassuringly: glargine is rapidly metabolized subcutaneously to metabolites with reduced IGF-1R binding, and the ORIGIN RCT plus meta-analyses show no clinically meaningful increase in overall cancer risk.[20](https://peptidevox.com/#r20)[21](https://peptidevox.com/#r21)[22](https://peptidevox.com/#r22) Insulin is also the established agent for hyperglycemia in pregnancy because it does not cross the placenta in meaningful amounts.[9](https://peptidevox.com/#r9)

The critical safety caveat for a peptide audience is non-medical misuse. Insulin is described in the sports-medicine literature as one of the most dangerous performance-enhancing drugs precisely because the margin between an "anabolic" dose and a lethal one is narrow and hypoglycemia onsets rapidly.[12](https://peptidevox.com/#r12) A published case describes a 30-year-old male bodybuilder in coma from severe, treatment-refractory hypoglycemia requiring iterative glucose infusions, ultimately traced to cryptic (concealed) insulin injections — the authors warn emergency physicians to suspect exogenous insulin in athletes with depressed consciousness and refractory hypoglycemia.[11](https://peptidevox.com/#r11) Survey data describe a predominantly young, male recreational-exerciser population frequently co-using anabolic steroids.[13](https://peptidevox.com/#r13)[14](https://peptidevox.com/#r14) There is no safe non-prescribed use.

## What is the FDA and WADA status in 2026?

Insulin is fully FDA-approved and foundational. Recombinant Humulin was approved on October 28, 1982, the first recombinant-DNA medicine of any kind (developed by Genentech and City of Hope, licensed to Eli Lilly).[18](https://peptidevox.com/#r18)[19](https://peptidevox.com/#r19) Numerous analogs and inhaled Afrezza (2014) are approved.[25](https://peptidevox.com/#r25) In March 2020 the FDA transitioned insulin and other proteins from the drug (NDA) pathway to the biologics (351) pathway under the BPCIA, enabling biosimilars and interchangeables; Semglee (insulin glargine-yfgn) became the first interchangeable biosimilar in the U.S. on July 28, 2021, permitting pharmacy-level substitution for Lantus.[27](https://peptidevox.com/#r27) Insulin is a prescription biologic but not a DEA-scheduled controlled substance — though it remains a high-alert medication, not a research chemical.

For athletes the picture is unambiguous. Under WADA's 2026 Prohibited List, in force January 1, 2026, insulin is prohibited at all times for non-diabetic athletes, listed under S4.4.2 "Insulins and Insulin-Mimetics" and as a peptide hormone under S2, with use permitted only via a valid Therapeutic Use Exemption for diabetes. The official list is published at [wada-ama.org](https://www.wada-ama.org/en/prohibited-list), and the WADA S4 category detail is catalogued by reference sources.[15](https://peptidevox.com/#r15)[16](https://peptidevox.com/#r16)[17](https://peptidevox.com/#r17)

**Bottom line.** Insulin is both the proof-of-concept that peptides are medicine and the cautionary archetype that a real, potent peptide hormone is not a supplement to be self-administered. Proven, Grade-A and life-saving in diabetes; lethal and unproven as a bodybuilding "anabolic." Regulatory and guideline facts here are current as of June 2026 and should be re-verified against the latest ADA Standards of Care and WADA Prohibited List.

---
Source: https://peptidevox.com/peptide-encyclopedia/insulin
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt